Y-mAbs Therapeutics (YMAB) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Company overview and leadership

• Commercial-stage biotech with a marketed pediatric oncology product, DANYELZA, targeting high-risk relapsed refractory neuroblastoma in children.

• Self-funding with cash runway into 2027 and minimal cash burn, enabling pipeline investment.

• Recent leadership changes include new general counsel, head of drug development with 40+ years in radiopharmaceuticals, and a new CFO.

DANYELZA product performance and strategy

• DANYELZA is the only humanized anti-GD2 antibody for pediatric neuroblastoma, offering outpatient treatment benefits.

• US market shows steady growth; ex-US expansion includes China, Hong Kong, Mexico, and Brazil, with further territories under consideration.

• Organizational restructuring focuses on maximizing DANYELZA's reach and advancing the radiopharmaceutical pipeline.

• Ongoing investment in lifecycle management and label expansion, including front-line neuroblastoma and osteosarcoma.

• Investigator-initiated trials explore additional indications such as Ewing sarcoma and triple-negative breast cancer.

Radiopharmaceutical pipeline and SADA platform

• SADA platform enables pre-targeted radioimmunotherapy, improving tumor specificity and reducing off-target toxicity.

• Platform allows non-radioactive drug administration followed by targeted isotope delivery, simplifying logistics and infrastructure needs.

• First two clinical programs target GD2 and CD38, leveraging prior antibody experience for rapid clinical entry.

• Platform is isotope-agnostic, supporting both diagnostic and therapeutic applications with flexibility in isotope selection.

• Additional targets in development include HER2 and B7-H3, with INDs targeted for end of 2025.